Google
Trusted Resources: News & Events
Latest announcements and gatherings
Diabetes Drug, Metformin, Suggested as ‘Breakthrough’ Treatment for Sickle Cell Anemia
Metformin, a common drug for Type 2 diabetes, could be used to “turn on” fetal hemoglobin levels in sickle cell anemia patients, according to a study by researchers at Baylor College of Medicine and Texas Children’s Cancer and Hematology Centers. The study’s lead investigator called the finding a “major breakthrough” in treating the disease.
Sickle cell patients’ adult hemoglobin causes their red blood cells to become sickle-shaped and get stuck inside the blood vessels, leading to pain and other complications. Fetal hemoglobin, a type of hemoglobin present in newborns, does not cause red blood cells to become sickle-shaped, but its production stops at about 6 months old.
+myBinderRelated Content
-
Development of a multi-center cohort to evaluate long-term outcomes and late effects following hematopoietic cell tr...Hematopoietic cell transplantation (HCT)...
-
Sickle cell patients in UK survey, especially those 16 to 20, voice problems with care and pain relief givenIn a survey, patients across the...
-
These patients had sickle-cell disease. Experimental therapies might have cured themScientists have long known what causes s...
-
GBT announces positive top-line data from part A of the phase 3 HOPE study of Voxelotor in sickle cell diseaseGlobal Blood Therapeutics, Inc. today an...
-
A Child Prodigy, a Painful Disease, and a Life-Changing Treatmenthttps://www.youtube.com/watch?v=SpzjD1ct...
-
Physician Prescribing Practices in Sickle Cell DiseaseSickle cell disease (SCD) affects approx...
-
Toronto Neuroscientist Getting Closer to Tailored Treatments for Chronic PainDaily tasks most people don't think too ...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.